FOLH1 and posterior cortical atrophy: While as nearly all treatment-naïve patients receiving PSMA-RGS had PSMA-positive PCa tumors expressing 10-100-fold more PSMA than surrounding benign prostatic tissues 5 and loss of PSMA expression is commonly observed in patients with CRPC who do not usually undergo further surgery, a well-performing PSMA single-targeted dye may suffice for most clinical needs in PSMA-RGS or PSMA-FGS, multi-targeted conjugates offer promise for patients with PCa tumors displaying low or reduced PSMA expression.